Researchers have recruited the first vaccine candidates to one of two new prevention trials that seek to immunize high-risk individuals against cancers associated with Lynch syndrome, the most common cause of hereditary colorectal cancer. Individuals who inherit the condition have an estimated… read more
POSTED: 02/08/2023
Chemopreventive Agent Development Research Group, Division of Cancer Prevention The National Cancer Institute (NCI), Division of Cancer Prevention (DCP), is seeking a Program Director to manage the formulation, production and distribution of small molecule and biologic agents for preclinical and… read more
POSTED: 01/12/2023
NCI funding graphic for CIN
The National Cancer Institute’s (NCI’s) Board of Scientific Advisors (BSA) recently approved two new concept proposals aimed at expanding potential prevention interventions.
POSTED: 01/10/2023
POSTED: 12/13/2022
AACR Annual Meeting 2022
April 8-13, 2022 DCP/PREVENT-funded Project Presentations Session OPO.IM01.01 - Tumor Immunobiology 5631 - Immunomodulatory activity of sulindac plus erlotinib for colon cancer prevention in familial adenomatous polyposisPresenter/Authors Chakrapani Tripathi, Roderick H. Dashwood. Texas A&M… read more
POSTED: 04/01/2022
Image of needle injecting vaccine in arm.
One of the first-ever vaccines for the prevention of colorectal and other cancers in patients at high genetic risk for these malignancies is expected to start its early phase safety and immunogenicity trial in the first quarter of 2022, according to investigators… read more
POSTED: 07/13/2021